Endpoints News

Merck partners with Flagship startup Quotient to search for genetic clues to IBD

Published

on

Quotient Therapeutics, a startup studying how tiny genetic typos cause some cells to get sick but allow others to remain healthy, has struck a partnership with Merck.
The partnership will identify new drug targets for …

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version